摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-fluorbenzyl)-6-(4-isopropoxyphenylamino)-3-isopropyl-1,3,5-triazine-2,4(1H,3H)-dion | 1239685-37-0

中文名称
——
中文别名
——
英文名称
1-(4-fluorbenzyl)-6-(4-isopropoxyphenylamino)-3-isopropyl-1,3,5-triazine-2,4(1H,3H)-dion
英文别名
1-(4-fluorobenzyl)-6-(4-isopropoxyphenylamino)-3-isopropyl-1,3,5-triazine-2,4(1H,3H)-dione;1-[(4-fluorophenyl)methyl]-3-propan-2-yl-6-(4-propan-2-yloxyanilino)-1,3,5-triazine-2,4-dione
1-(4-fluorbenzyl)-6-(4-isopropoxyphenylamino)-3-isopropyl-1,3,5-triazine-2,4(1H,3H)-dion化学式
CAS
1239685-37-0
化学式
C22H25FN4O3
mdl
——
分子量
412.464
InChiKey
CFGDBJCENZPXFT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    30
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    74.2
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION HAVING AN ANALGESIC ACTIVITY COMPRISING THE SAME
    申请人:Kai Hiroyuki
    公开号:US20130172317A1
    公开(公告)日:2013-07-04
    The present invention provides novel compounds having a P2X 3 and/or P2X 2/3 receptor antagonistic effect. A pharmaceutical composition having an analgesic effect or an improving effect of urination disorder comprising a compound of the formula (I): wherein R h and R j are taken together to form a bond; R a and R b and/or R d and R e are taken together to form oxo or the like; R c is hydrogen, substituted or unsubstituted alkyl or the like; R f is —(CR 4a R 4b ) n —R 2 ; R 4a and R 4b are hydrogen, substituted or unsubstituted alkyl or the like; R 2 is substituted or unsubstituted cycloalkyl or the like; n is an integer of 1 to 4; —R g is —X—R 3 ; —X— is —O—, —S— or the like; R 3 is substituted or unsubstituted cycloalkyl or the like, or its pharmaceutically acceptable salt or a solvate thereof.
    本发明提供了具有P2X3和/或P2X2/3受体拮抗作用的新型化合物。一种具有镇痛作用或改善排尿障碍作用的药物组合物,包括式(I)的化合物:其中Rh和Rj结合形成键;Ra和Rb和/或Rd和Re结合形成氧化物或类似物;Rc是氢、取代或未取代的烷基或类似物;Rf是-(CR4aR4b)n-R2;R4a和R4b是氢、取代或未取代的烷基或类似物;R2是取代或未取代的环烷基或类似物;n是1到4的整数;-R是-X-R3;-X-是-O-、-S-或类似物;R3是取代或未取代的环烷基或类似物,或其药学上可接受的盐或其溶剂化物。
  • NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
    申请人:Shionogi & Co., Ltd.
    公开号:EP2399910A1
    公开(公告)日:2011-12-28
    The present invention provides a novel P2X3 and/or P2X2/3 receptor antago nist. A compound represented by the formula (I): wherein Ra, Rb and Rc are, (a) Ra and Rb are taken together =Z; and Rc is a group represented by R1c; or (b) Rb and Rc are taken together to form a bond; and Ra is a group represented by -Y-R1a; R1a and R1c are each independently hydrogen, substituted or unsubstituted alkyl, etc.; R2 and R3 are each independently substituted or unsubstituted aryl, etc.; R4a and R4b are each independently hydrogen, substituted or unsubstituted alkyl, etc.; X is -N(R5)-, etc.; R5 is hydrogen, substituted or unsubstituted lower alkyl, etc.; -Y- is -O-, etc.; =Z is =O, etc.; and n is an integer of 0 to 4.
    本发明提供了一种新型 P2X3 和/或 P2X2/3 受体拮抗剂。 由式(I)代表的化合物: 其中 Ra、Rb 和 Rc 为 (a) Ra 和 Rb 合起来=Z;而 Rc 是由 R1c 代表的基团;或 (b) Rb 和 Rc 合在一起形成键;Ra 是由-Y-R1a 所代表的基团; R1a 和 R1c 各自独立地为氢、取代或未取代的烷基等; R2 和 R3 各自独立地为取代或未取代的芳基等; R4a 和 R4b 各自独立地是氢、取代或未取代的烷基等; X 是 -N(R5)- 等; R5 是氢、取代或未取代的低级烷基等; -Y-是-O-等; =Z 是 =O等;以及 n 是 0 至 4 的整数。
  • TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOUND THAT CONTAINS SAME AND EXHIBITS ANALGESIC ACTIVITY
    申请人:Shionogi & Co., Ltd.
    公开号:EP2604595A1
    公开(公告)日:2013-06-19
    The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect. A pharmaceutical composition having an analgesic effect or an improving effect of urination disorder comprising a compound of the formula (I): wherein Rh and Rj are taken together to form a bond; Ra and Rb and/or Rd and Re are taken together to form oxo or the like; Rc is hydrogen, substituted or unsubstituted alkyl or the like; Rf is -(CR4aR4b)n-R2; R4a and R4b are hydrogen, substituted or unsubstituted alkyl or the like; R2 is substituted or unsubstituted cycloalkyl or the like; n is an integer of 1 to 4; -Rg is -X-R3; -X- is -O-, -S- or the like; R3 is substituted or unsubstituted cycloalkyl or the like, or its pharmaceutically acceptable salt or a solvate thereof.
    本发明提供了具有 P2X3 和/或 P2X2/3 受体拮抗作用的新型化合物。 一种具有镇痛效果或改善排尿障碍效果的药物组合物,由式(I)化合物组成: 其中 Rh 和 Rj 共同形成键;Ra 和 Rb 和/或 Rd 和 Re 共同形成氧代或类似物;Rc 是氢、取代或未取代的烷基或类似物; Rf是-(CR4aR4b)n-R2;R4a和R4b是氢、取代或未取代的烷基或类似物;R2是取代或未取代的环烷基或类似物;n是1至4的整数;-Rg是-X-R3;-X-是-O-、-S-或类似物;R3是取代或未取代的环烷基或类似物、 或其药学上可接受的盐或其溶液。
  • EP2604595
    申请人:——
    公开号:——
    公开(公告)日:——
  • EP2604595B1
    申请人:——
    公开号:EP2604595B1
    公开(公告)日:2016-03-16
查看更多